12:00 AM
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lu AE58054: Phase II data

A double-blind, international Phase II trial in 278 patients with moderate AD showed that oral Lu AE58054 as an add-on to Aricept donepezil met the primary endpoint of improving ADAS-Cog scores from baseline to week 24...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >